179 related articles for article (PubMed ID: 17397536)
1. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.
Zheng J; Kohler ME; Chen Q; Weber J; Khan J; Johnson BD; Orentas RJ
BMC Immunol; 2007 Mar; 8():4. PubMed ID: 17397536
[TBL] [Abstract][Full Text] [Related]
2. Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade.
Zheng J; Jing W; Orentas RJ
Acta Biochim Biophys Sin (Shanghai); 2009 Dec; 41(12):980-90. PubMed ID: 20011972
[TBL] [Abstract][Full Text] [Related]
3. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
Zheng J; Liu P; Yang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
[TBL] [Abstract][Full Text] [Related]
4. Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade.
Zheng J; Orentas R; Yan X; Liu H
Acta Biochim Biophys Sin (Shanghai); 2011 Feb; 43(2):124-32. PubMed ID: 21266542
[TBL] [Abstract][Full Text] [Related]
5. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.
Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH
Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140
[TBL] [Abstract][Full Text] [Related]
6. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
Johnson BD; Jing W; Orentas RJ
J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
[TBL] [Abstract][Full Text] [Related]
7. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
[TBL] [Abstract][Full Text] [Related]
9. Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity.
Rigo V; Corrias MV; Orengo AM; Brizzolara A; Emionite L; Fenoglio D; Filaci G; Croce M; Ferrini S
Cancer Immunol Immunother; 2014 May; 63(5):501-11. PubMed ID: 24647609
[TBL] [Abstract][Full Text] [Related]
10. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
[TBL] [Abstract][Full Text] [Related]
11. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
Todo T; Martuza RL; Dallman MJ; Rabkin SD
Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
[TBL] [Abstract][Full Text] [Related]
12. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
Chen PW; Ksander BR
Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
[TBL] [Abstract][Full Text] [Related]
14. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
15. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
16. Anti-idiotype responses abrogate anti-CD4-induced tolerance to a tumor-specific antigen and promote systemic tumor immunity.
Kennedy RC; Shearer MH; Lowe DB; Jumper CA; Chiriva-Internati M; Bright RK
Cancer Immunol Immunother; 2004 Nov; 53(11):987-94. PubMed ID: 15156293
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.
Kohler ME; Johnson BD; Palen K; Chen QR; Khan J; Orentas RJ
Cancer Sci; 2010 Nov; 101(11):2316-24. PubMed ID: 20718755
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells.
Kim TS; Chopra A; O-Sullivan IS; Cohen EP
J Immunother; 2006; 29(3):261-73. PubMed ID: 16699369
[TBL] [Abstract][Full Text] [Related]
19. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
20. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
